NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced that the Company will virtually present at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
Presentation Information
Event: | H.C. Wainwright 25th Annual Global Investment Conference |
Time: | Presentation to be accessible on-demand, beginning 7:00 AM EDT, Monday, September 11, 2023 |
Presenter: | Alon Seri-Levy, Chief Executive Officer |
Format: | Virtual presentation |
Registration: | Link |
About Sol-Gel Technologies
Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to and commercialized by Galderma in the U.S.
The Company’s pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and also includes topical drug candidate SGT-210 for the treatment of rare skin keratodermas, which had positive results in a Phase 1 study.
For additional information, please visit www.sol-gel.com.
For further information, please contact:
Investors:
Irina Koffler
Investor relations, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 917 734 7387
Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.55 |
Daily Change: | 0.07 14.58 |
Daily Volume: | 5,751,366 |
Market Cap: | US$15.320M |
April 17, 2025 November 15, 2024 August 16, 2024 May 20, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load